Objective. To determine the effect of medical treatment on work disability in patients with active PsA in a real-world setting.
Introduction
Prospective cohort studies have demonstrated progressive joint damage, reduced quality of life and high levels of disability in patients with PsA [14] . There is growing evidence to indicate that early diagnosis and treatment can ameliorate disease activity, reduce joint damage and prevent disability [58] .
There is increasing recognition by clinicians, patient groups and regulatory agencies of the importance of measuring the effect of treatment with 'real-world' outcomes important to patients, thereby capturing all the ways in which disease affects the individual [9, 10] . When assessing the effect of treatment, outcome measures such as joint counts or biomarkers may not capture all aspects of disease and may even be discordant with patientreported outcomes and, as a result, fail to capture important benefits to patients [11] . Work disability has become a particularly important outcome in the evaluation of chronic inflammatory rheumatic disease [12, 13] . Work disability was ranked as a highly important outcome by patients in the EULAR-led The PsA Impact of Disease (PSAID) study [14] . The PsA Impact of Disease was developed specifically for use in PsA as a patient-centred, patient-reported outcome of impact of disease to capture all the ways in which PsA affects an individual. Patients ranked impacts of disease in order of importance and work was ranked fourth behind pain, skin and fatigue [14] .
There are high rates of work disability in PsA. Estimates of unemployment and work disability range from 2050% to 1639%, respectively, in clinical trials and cohort studies [3] . Presenteeism (reduced effectiveness at work) and productivity loss (presenteeism plus absenteeism) have been shown to be primarily associated with disease activity in PsA, raising the possibility that amelioration of active disease may lead to reduced work disability [15] .
In the present study we set out to assess the effect of medical treatment on work disability in patients with active PsA in an unselected population of patients undergoing a change in medication as part of routine clinical practice in the UK.
Methods
The study design for Long Term Outcomes in PsA II (LOPAS II) has previously been reported [15] . In brief, LOPAS II is a prospective multicentre observational cohort study to investigate work disability in PsA and the effect of treatment. Twenty-three sites across the UK participated in the study (supplementary Fig. 1 , available at Rheumatology Online). Four hundred patients of any age and disease duration who fulfilled the classification criteria for PsA (CASPAR) [16] and who were being commenced on conventional synthetic DMARDs (csDMARDs) or anti-TNF as part of routine clinical care were recruited. Any patients commencing a csDMARD or anti-TNF were eligible for inclusion, including new monotherapy, combination treatment and switching agents. The sample size was calculated to achieve 80% power to detect the minimal clinically important difference of 7% [17] change in presenteeism at a 5% level of significance. Patients <18 years of age or non-English speaking were excluded. Physician-and patient-reported outcome measures were collected at routine clinic appointments at baseline and at 3 and 6 months, with additional patient-reported outcomes only by mail at weeks 2 and 4. Study recruitment occurred between September 2011 and April 2013. LOPAS II, including this study, was approved by the South Wales Research Ethics Committee Panel D. All patients signed written consent in accordance with the Declaration of Helsinki.
Work disability was assessed with the work productivity and activity impairment (WPAI) questionnaire [18] . The WPAI is a six-item patient-reported questionnaire asking patients to report the degree to which they experience difficulty at work due to a specific health problem, in this case PsA over the preceding week. Four outcomes can be generated from the WPAI, expressed in percentages: absenteeism (absence from work), presenteeism (reduced effectiveness at work), productivity loss (a function of both absenteeism and presenteeism) and general activity impairment attributable to a specific health problem.
The WPAI has been validated for use in RA and AS and the presenteeism measure by OMERACT [1921] . Peripheral joint disease activity was measured using the composite disease activity in PsA (DAPSA) score, a summation of 66 swollen and 68 tender joint counts, CRP and patient global and pain visual analogue scale (VAS) scores [22] . Patient-reported outcomes included physical function with the HAQ, the EuroQol five-dimensions questionnaire (EQ-5D), dermatology quality of life index (DLQI), Functional Assessment of Chronic Illness Therapy (FACIT) fatigue scale and global/domain-specific activity VAS scores.
This study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines for the reporting of cohort studies [23] .
Statistical analysis
All analysis was performed using the statistical package R 2014 (R Project for Statistical Computing, Vienna, Austria) [24] . Univariate comparisons between treatment groups at baseline were performed using Wilcoxon tests. Differences within groups were made on an intention-totreat basis (excluding seven patients who were never issued a prescription). Multiple imputation, based on both the available data and underlying temporal patterns within responses for each patient, was used to infer values of missing predictor data using the Amelia II package in R [25] . Changes in the responses over time are presented as plots of mean values by time points. Regression modelling was used to model rates of improvements using actual dates (rather than planned time points) and the effects of potential predictor variables.
Rates of improvement, using actual dates rather than planned time points, were modelled using regression models with missing values in explanatory variables estimated using multiple imputation. P-values for significance tests of potential differences between rates of improvement in different groups, defined either by treatment or duration of disease, were obtained by including interaction terms in these regression models. WPAI response variables were recorded in (or categorized to) groups representing deciles and multivariate Poisson regression models were used to formally assess changes over time. Differences in rates of improvement were assessed allowing for age, sex, disease duration, baseline HAQ, DAPSA and EQ-5D. To allow for the expected excess of zeros in the response variables, zero-inflated Poisson models were used, with a consistent set of covariates used for both the binomial and Poisson components of the model.
Results
The mean age of patients was 46.8 years (S.D. 11.02), the mean disease duration was 5.8 years (S.D. 8.00) and 49.9% were female. A total of 226 patients of working age (64%) were in work, with a further 10 over retirement age still working. Ninety-two patients of working age (26%) were unemployed. Table 1 illustrates the baseline characteristics of all patients who were commenced on anti-TNF and DMARD therapy. A supplementary file (supplementary Table 1 , available at Rheumatology Online) compares the baseline characteristics of working-age employed and unemployed patients at baseline. Unemployed patients had worse physical function than those who were employed (HAQ 1.5 and 0.88, respectively, P < 0.001) and worse quality of life (EQ-5D 0.71 and 0.78, respectively, P < 0.001).
Follow-up time points and loss to follow-up
Seven of the 400 patients recruited did not commence a drug and were excluded from the analysis. A total of 63 patients did not complete 6 months of follow-up. Fortynine patients became lost to follow-up and a further 14 withdrew from the study (two became pregnant, two developed cancer, one relocated, nine cited personal reasons), two patients had their diagnosis changed to OA and one patient died of an unrelated condition. Figure 1 illustrates the study recruitment and follow-up by treatment group and those included in the work analysis. There were no statistically significant differences in www.rheumatology.oxfordjournals.org demographic or baseline disease characteristics between those lost to follow-up and those who remained in the study.
Drugs commenced during LOPAS II
Of the 272 patients who started (including switching and step-up combination treatment) csDMARDs, 54% started MTX, 30% SSZ, 12% LEF, 1% ciclosporin, 1% AZA, 1% HCQ and 1% combination treatment. Of the 121 who commenced anti-TNF (including switching and step-up combination treatment), 56% commenced adalimumab, 35% etanercept, 5% infliximab and 4% golimumab. The planned study clinical follow-up was 'per routine care', with clinical assessment at 3 and 6 months. Additional patient-reported questionnaires were completed at 2 and 4 weeks by mail. There was variation in the times at which patients were seen; the medians for days from baseline for the five time points were 14 [interquartile range (IQR) 1426], 28 (2842), 98 (89119) and 196 (179224).
Work disability and clinical outcome
One hundred and sixty-four of the 272 patients commenced on a csDMARD and 65 of the 121 commenced on anti-TNF were working (Fig. 1) . Over 6 months of follow-up, those commenced on csDMARDs had a 10% improvement in presenteeism (IQR 3020; P = 0.007) and a 15% improvement in productivity loss (IQR 4025; P = 0.001). Patients commenced on anti-TNF had a 30% improvement in presenteeism (IQR 4010; P < 0.001) and a 40% improvement in productivity loss (IQR 5010; P < 0.001). Improvement was more rapid and of a greater magnitude among those commenced on anti-TNF (Fig. 2) . Although absenteeism did improve, this improvement was not statistically significant.
Clinical improvement was measured using the DAPSA composite index. Patients commenced on a csDMARD had an 8.4 point improvement (IQR 38.630.2; P < 0.0001). Patients commenced on anti-TNF had a 36.8 point improvement (IQR 50.814.0) (Fig. 3) . Sixtyfive per cent of those commencing anti-TNF achieved a 50% response in DAPSA vs 26% of those commencing a csDMARD. Tables 2 and 3 summarize the individual changes in patient-reported and clinical outcomes during the course of 6 months of follow-up. Patients commenced on anti-TNF had achieved improvements in all outcomes and these improvements exceeded the minimally important difference (MID) in global activity [26] , pain [26] , physical function (HAQ) [26] , fatigue (FACIT) [27] and quality of life (EQ-5D) [28] , but not skin-specific quality of life (DLQI) [29] . Smaller, but statistically significant improvements were observed among patients commenced on csDMARDs, although improvements greater than the MID were only observed in global activity, pain and fatigue. The changes in global, pain, joint and skin-specific VAS, HAQ, DAPSA, FACIT and DLQI among both groups are illustrated in Fig. 3 .
A subanalysis was performed to investigate whether the greater change seen in patients receiving anti-TNF vs csDMARD might be sensitive to baseline disease activity. Those starting on anti-TNF had higher disease activity and therefore may have a greater scope for improvement. It was found that the rate of improvement of presenteeism, productivity loss and activity impairment in anti-TNF vs DMARD treatment was seen in patients with both high and low baseline disease activity. The rates of improvement in absenteeism were slower among those with low disease activity.
Work disability-rates of change during follow-up
Given the observational nature of the study, there was variance in follow-up around each planned follow-up time point. In order to assess differences in the rate of change over time, analyses were undertaken by exact time point (days). Significant decreases were found in all WPAI domains (absenteeism, presenteeism, productivity loss and activity impairment) during follow-up (P < 0.0001). Patients commenced on anti-TNF improved more rapidly than those on csDMARDs in all WPAI domains (P < 0.001 for differences in the rate of improvement).
Work disability and disease duration
A total of 292 patients had complete recorded data for onset of disease, with 83 patients recorded as having a disease duration of 42 years and 209 with >2 years at baseline. Previously identified clinical and demographic predictor variables were included in the regression, including age, disease duration, global and joint VAS scores, HAQ and employer helpfulness [15] . Patients with a shorter duration had significantly higher activity loss (P = 0.002), presenteeism (P = 0.003), absenteeism (P < 0.001) and productivity loss (P = 0.008) at baseline. There was a statistically greater improvement in productivity loss among those with a disease duration of <2 years.
Discussion
We report improvement in work disability, clinical and patient-reported outcome among a cohort of patients in the   FIG. 1 Loss to follow-up during the LOPAS II study UK commenced on anti-TNF and csDMARDs for active PsA as part of their routine care. Improvements in all outcomes were more rapid and of greater magnitude among those commenced on anti-TNF despite higher levels of baseline disease activity. Notably, the gain in work productivity with anti-TNF was even greater with a shorter duration disease. Clinical and patient-reported outcome response to csDMARDs was poor, achieving MID improvements in pain/global VAS and fatigue alone. To our knowledge, LOPAS II is the first study of its type sufficiently powered to use work disability as the primary end point.
There has been interest in the effect of treatment on work disability in long-term rheumatic diseases-in particular, studies comparing different classes of drug treatment. Many of the recent randomized controlled trials of novel therapeutic agents in PsA have included work as a secondary end point [3032] . Comparison of biologics and csDMARDs in RA have demonstrated reduced absenteeism, reduced sick leave, higher employment potential and greater levels of employment potential among those treated with biologics [33] . The data we present in this present study describes the differential effect of anti-TNF and csDMARDs on patient-reported work disability (presenteeism and productivity loss) in a well-classified group of patients with PsA in a real-world setting. The work disability data we report are attributable to PsA (using the WPAI Specific Health Problem) and is granular (over the last week), minimizing recall bias. The study is further strengthened by using well-defined patients (CASPAR criteria), multicentre recruitment across the UK and broad inclusion criteria (encompassing patients of any age and disease duration), which increases the generalizability of the findings.
While there is recognition that work is an important outcome, there has been debate about how to use the measure and interpret work data. It has been argued that there are too many contextual factors to justify wider uptake of work as a disease outcome measure. Recognizing these concerns, the OMERACT core set of domains for PsA   FIG. 2 Work outcome among working participants commenced on anti-TNF (n = 65) and csDMARDs (n = 164) www.rheumatology.oxfordjournals.org controlled trials and observational studies placed participation (including work) in the outer circle for further research [34] . The findings of this study support the view that contextual factors may have less impact in the context of active disease than previously thought, particularly with respect to measures of in-work disability [33] . We have previously reported that measures of reduced effectiveness at work (presenteeism and productivity loss) are more strongly associated with disease activity than disease severity (damage) or contextual measures [15] . Work disability has also been found to be associated with fatigue in PsA [35] . Now, in this present study, as in the highly selected populations of novel biologic agent randomized controlled trials, we have observed that work disability improves in parallel with clinical disease activity despite contextual factors. The finding that disease duration of <2 years is associated with more rapid improvement is of clinical interest, particularly because unemployment is often irreversible, and this may add to the building case for early intervention in newly diagnosed PsA. Our results support the role for work disability as an effective, patient-centred disease outcome measure of participation.
The clinical improvement seen after commencing anti-TNF and the relative lack of response among csDMARDs in this study is striking. The effectiveness of anti-TNF in PsA is well established, whereas studies of csDMARDs are limited [36] . Many of the csDMARD studies were conducted before the modern era of more aggressive treatment with higher doses, combination therapy and a treat-to-target approach. The results of this observational cohort study have shown that among 272 patients commenced on csDMARDs as part of routine care, improvement in clinical, biochemical and patient-reported measures was slow and of small magnitude. As this was an observational study, we did not influence csDMARD choice or dosing, and it is possible that some of the poor response may be related to lower dosing, differing dose escalation regimes and inclusion of drugs that may be less efficacious in PsA. Finally, we should also note there is an ongoing trend towards improvement in the csDMARD group (Fig. 3) that may become significant with longer follow-up.
When interpreting the findings of this study it is important to highlight certain methodological limitations. LOPAS II was an observational study, so direct comparison cannot be made between treatment groups. Patients were recruited at a point of high disease activity, thus some improvement over the course of the study may be   FIG. 3 Clinical outcomes among participants commenced on anti-TNF (n = 121) and csDMARDs (n = 272) related to the natural relapsingremitting course of disease. It is our view that this effect would have been small, first, as patients commencing anti-TNF were in sustained flare (as part of their eligibility for anti-TNF in the National Health Service, having failed csDMARDs) and, second, because of the limited improvement seen among those commenced on csDMARDs. Finally, it is important to recognize that the DAPSA is a measure of articular disease in PsA rather than a composite outcome measure capturing all domains of disease. The DAPSA does not capture other important domains of disease (enthesitis, skin, dactylitis, axial involvement) except indirectly through the global VAS score.
In conclusion, we report data from a large observational cohort study on the effect of medical treatment with anti-TNF or csDMARDs commenced as part of routine care on patient-reported work disability and clinical outcome. Work disability and clinical outcome improved quickly to clinically significant levels among those commenced on anti-TNF despite high levels of disease activity. Improvements in work disability occurred more slowly and were of a smaller magnitude and clinical improvement was poor among those commenced on csDMARDs. These data support the view that work disability is reversible with effective treatment of active disease in the real-world setting. www.rheumatology.oxfordjournals.org teams. We would like to thank Nicola Waldron, nurse specialist in PsA, Charlotte Cavill, our database manager, and Mandy Knight and Austin Smith, our database administrators. L.J.K. is a Generation Q Fellow with the Health Foundation.
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